Advertisement

Igf-1 And The Heart

  • Marc Y Donath
  • Juergen Zapf
Part of the Endocrine Updates book series (ENDO, volume 9)

Abstract

The so-called somatomedin hypothesis (1) states that growth hormone (GH) acts on skeletal tissues indirectly by inducing the production of a growth factor, somatomedin, circulating in blood and mediating the effects of GH on growth. After the isolation and amino sequencing of insulin-like growth factor I (IGF I) and its biological characterization it became evident that this polypeptide was the postulated somatomedin. IGF I consists of 70 amino acids and has a molecular weight of 7649 (2). It is mainly produced and secreted by the liver. However, many other tissues synthesize IGF I which acts locally on these tissues. The significance of endocrine versus auto-/paracrine actions of IGF I is still under debate. Two recent publications provide evidence that in mice liver-derived circulating IGF I is not required for growth (3, a). IGF I tissue expression is under the control of GH (5), but other factors, like insulin or nutrition, also influence IGF I production. Both endogenous and administered IGF I mimic trophic effects of pituitary GH. In contrast, some effects of administered IGF I on intermediary metabolism are opposite to those of GH (6, 7). Moreover, the two hormones act by different mechanisms, which implies that endogenous IGF I induced by GH does in general not mediate the effects of GH on intermediary metabolism. Cardiac effects of IGF were first investigated by Meuli and Froesch in 1975 in the perfused rat heart (8). IGF, like insulin, stimulated glucose transport and lactate production. The biological potency ratio between IGF and insulin in this model was higher than in adipose tissue. Based on this finding and on competitive binding studies, it was concluded that insulin and IGF act on the heart separately via the insulin and the type 1 IGF receptor, respectively (9). In 1986 Borner and Froesch showed that IGF I stimulated the contractility of the isolated perfused rat heart (Figure 1). Since the availability of pure IGF I was limited at that time the positive inotropic effects of IGF I could not be extensively tested, and the data remained unpublished.

Keywords

Growth Hormone Cardiac Hypertrophy Atrial Natriuretic Factor Positive Inotropic Effect Acute Cardiovascular Effect 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Daughaday WH, Hall K, Raben MS, et al. Somatomedin: proposed designation for sulphation factor. Nature 1972; 235(5333):107.PubMedCrossRefGoogle Scholar
  2. 2.
    Humbel RE. Insulin-like growth factors I and II. Eur J Biochem 1990; 190:445–462.PubMedCrossRefGoogle Scholar
  3. 3.
    Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, LeRoith D. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 1999; 96(13):7324–7329.PubMedCrossRefGoogle Scholar
  4. 4.
    Sjogren K, Liu JL, Blad K, Skrtic S, Vidal 0, Wallenius V, LeRoith D, Tornell J, Isaksson OG, Jansson JO, Ohlsson C. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. Proc Natl Acad Sci USA 1999; 96(12):7088–7092.PubMedCrossRefGoogle Scholar
  5. 5.
    Gosteli-Peter MA, Winterhalter KH, Schmid C, Froesch ER, Zapf J. Expression and regulation of insulin-like growth factor-I (IGF-I) and IGF-binding protein messenger ribonucleic acid levels in tissues of hypophysectomized rats infused with IGF-I and growth hormone. Endocrinol 1994; 135:2558–2567.CrossRefGoogle Scholar
  6. 6.
    Hussain MA, Schmitz O, Mengel A, Keller A, Christiansen JS, Zapf J, Froesch ER. Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in humans. J Clin Invest 1993; 92:2249–2256.PubMedCrossRefGoogle Scholar
  7. 7.
    Hussain MA, Schmitz O, Mengel A, Glatz Y, Christiansen JS, Zapf J, Froesch ER. Comparison of the effects of growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans. J Clin Invest 1994; 94: 1126–1133.PubMedCrossRefGoogle Scholar
  8. 8.
    Meuli C, Froesch ER. Effects of insulin and of NSILA-S on the perfused rat heart: glucose uptake, lactate production and efflux of 3–0-methyl glucose. Europ J Clin Invest 1975; 5:93–99.PubMedCrossRefGoogle Scholar
  9. 9.
    Meuli C, Froesch ER. Binding of insulin and nonsuppressible insulin-like activity to isolated perfused rat heart muscle. Arch Biochem Biophys 1976; 177:31–38.PubMedCrossRefGoogle Scholar
  10. 10.
    Guler HP, Zapf J, Scheiwiller E, Froesch ER. Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats. Proc Natl Acad Sci USA 1988; 85: 4889–4893.PubMedCrossRefGoogle Scholar
  11. 11.
    Florini JR, Ewton DZ. Induction of gene expression in muscle by the IGFs, Growth Regul 1992; 2:23–29.PubMedGoogle Scholar
  12. 12.
    Fuller SJ; Mynett JR; Sugden PH. Stimulation of cardiac protein synthesis by insulin-like growth factors. Biochem J 1992; 282:85–90.PubMedGoogle Scholar
  13. 13.
    Ito H, Hiroe M, Hirata Y, Tsujino M, Adachi S, Shichiri M, Koike A, Nogami A, Marumo F. Insulin-like growth factor-I induces hypertrophy with enhanced expression of muscle specific genes in cultured rat cardiomyocytes. Circulation 1993; 87:1715–1721.PubMedCrossRefGoogle Scholar
  14. 14.
    Donath MY, Zapf J, Eppenberger-Eberhardt M, Froesch ER, Eppenberger HM. Insulin-like growth factor I stimulates myofibril development and decreases smooth muscle alpha actin of adult cardiomyocytes. Proc Natl Acad Sci USA 1994; 91:1686–1690.PubMedCrossRefGoogle Scholar
  15. 15.
    Eppenberger-Eberhardt M, Aigner S, Donath MY, Kurer V, Walther P, Zuppinger C, Schaub MC, Eppenberger HM. IGF-I and bFGF differentially influence atrial natriuretic factor and alpha-smooth muscle actin expression in cultured atrial compared to ventricular adult rat cardiomyocytes. J Mol Cell Cardiol 1997; 29(8):2027–2039.PubMedCrossRefGoogle Scholar
  16. 16.
    Parker TG, Packer SE, Schneider MD. Peptide growth factors can provoke “fetal” contractile protein gene expression in rat cardiac myocytes. J Clin Invest 1990; 85:507–514.PubMedCrossRefGoogle Scholar
  17. 17.
    Schneider MD, Parker TG. Cardiac myocytes as targets for the action of peptide growth factors. Circulation. 1990; 81:1443–1456.PubMedCrossRefGoogle Scholar
  18. 18.
    Morgan HE, Gordon EE, Kira Y, Chua BHL, Russo LA, Peterson CJ, McDermott PJ, Watson PA. Biochemical mechanisms of cardiac hypertrophy. Annu Rev Physiol 1987; 49:533–543.PubMedCrossRefGoogle Scholar
  19. 19.
    Parker TG, Chow K-L, Schwartz RJ, Schneider MD. Differential regulation of skeletal alpha-actin transcription in cardiac muscle by two fibroblast growth factors. Proc. Natl. Acad. Sci. USA 1990; 87:7066–7070.PubMedCrossRefGoogle Scholar
  20. 20.
    Chien KR, Knowlton KU, Zhu H, Chien S. Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J 1991; 5(15):3037–3046.PubMedGoogle Scholar
  21. 21.
    Black FM, Packer SE, Parker TG, Michael LH, Roberts R, Schwartz RJ, Schneider MD. The vascular smooth muscle a-actin is reactivated during cardiac hypertrophy provoked by load. J Clin Invest 1991; 88:1581–1588.PubMedCrossRefGoogle Scholar
  22. 22.
    Schwartz K, de la Bastie D, Bouveret P, Oliviéro P, Alonso S, Buckingham M. a-skeletal muscle actin mRNAs accumulate in hypertrophied adult rat hearts. Circ Res 1986; 59:551–555.PubMedCrossRefGoogle Scholar
  23. 23.
    Izumo S, Lompre AM, Matsuoka R, Koren G, Schwartz K, Nadal-Ginard B, Mandavi V. Myosin heavy chain messenger RNA and protein isoform transitions during cardiac hypertrophy. Interaction between hemodynamic and thyroid hormone-induced signals. J Clin Invest. 1987; 79:970–977.PubMedCrossRefGoogle Scholar
  24. 24.
    Lattion A-I, Michel J-B, Arnauld E, Corvol P, Sourbier F. Myocardial recruitment during ANF mRNA increase with volume overload in the rat. Am J Physiol 1986; 251:H890–H896.PubMedGoogle Scholar
  25. 25.
    Izumo S, Nadal-Ginard B, Mandavi V. Protooncogene induction and reprogramming of cardiac expression produced by pressure overload. Proc Natl Acad Sci USA 1988; 85:339–343.PubMedCrossRefGoogle Scholar
  26. 26.
    Mercadier J-J, Samuel J-L, Michel JB,Zongazo MA, de-la-Bastie D, Lompre A-M, Wisnewsky C, Rappaport L, Levy B, Schwartz K. Atrial natriuretic factor gene expression in rat ventricle during experimental hypertension. Am J Physiol 1989; 257:H979–H987.PubMedGoogle Scholar
  27. 27.
    Wâhlander H, Isgaard J, Jennische E, Friberg P. Left ventricular insulin-like growth factor I increases in early renal hypertension. Hypertension 1992; 19:25–32.PubMedCrossRefGoogle Scholar
  28. 28.
    Russell-Jones DL, Leach RM, Ward JPT, Thomas CrR. Insulin-like growth factor-I gene expression is increased in the right ventricular hypertrophy induced by chronic hypoxia in the rat. J Mol Endocrinol 1993; 10:99–102.PubMedCrossRefGoogle Scholar
  29. 29.
    Hanson MC, Fath KA, Alexander RW, Delafontaine P. Induction of cardiac insulin-like growth factor I gene expression in pressure overload hypertrophy. Am J Med Sci. 1993; 306(2):69–74.PubMedCrossRefGoogle Scholar
  30. 30.
    Donohue TJ, Dworkin LD, Lango MN, Fliegner K, Lango RP, Benstein JA, Slater WR, Catanese VM. Induction of myocardial insulin-like growth factor-I gene expression in left ventricular hypertrophy. Circulation 1994; 89:799–809.PubMedCrossRefGoogle Scholar
  31. 31.
    Isgaard J, Wahlander H, Adams MA, Friberg P Increased expression of growth hormone receptor mRNA and insulin-like growth factor-I mRNA in volume-overloaded hearts. Hypertension 1994; 23:884–888.PubMedCrossRefGoogle Scholar
  32. 32.
    Toyozaki T, Hiroe M, Hasumi M, Horie T, Hosoda S, Tsushima T, Sekiguchi M. Insulin-like growth factor I receptors in human cardiac myocytes and their relation to myocardial hypertrophy. Jpn Circ J 1993; 57:1120–1127.PubMedCrossRefGoogle Scholar
  33. 33.
    Donath MY, Gosteli-Peter MA, Hauri C, Froesch ER, Zapf J. Insulin-like growth factor I stimulate myofibrillar genes and modulates atrial natriuretic factor mRNA in rat heart. Eur J Endocrinol 1997; 137:309–315.PubMedCrossRefGoogle Scholar
  34. 34.
    Donath MY, Zierhut W, Gosteli-Peter MA, Hauri C, Froesch ER, Zapf J. Effects of IGF-I on cardiac growth and expression of mRNAs coding for cardiac proteins after induction of heart hypertrophy in the rat. Eur J Endocrinol 1998; 139:109–117.PubMedCrossRefGoogle Scholar
  35. 35.
    Vetter U, Kupferschmid C, Lang D, Benz S. Insulin-like growth factors and insulin increases the contractility of neonatal rat cardiocytes in vitro. Basic Research Cardiol 1988; 83:647–654.CrossRefGoogle Scholar
  36. 36.
    Freestone NS; Ribaric S; Mason WT, The effect of insulin-like growth factor I on adult rat cardiac contractility. Mol Cell Biochem 1996; 163/164:223–229.PubMedCrossRefGoogle Scholar
  37. 37.
    Ren J, Walsh MF, Hamaty M, Sowers JR, Brown RA. Altered inotropic response to IGFI in diabetic rat heart: influence of intracellular Ca2+ and NO. Am J Physiol 1998; 275:1823–830.Google Scholar
  38. 38.
    Kinugawa S, Tsutsui H, Ide T, Nakamura R, Arimura K-I, Egashira K, Takeshita A. Positive inotropic effect of insulin-like growth factor-1 on normal and failing cardiac myocytes. Cardiovascular Research 1999; 43:157–164.PubMedCrossRefGoogle Scholar
  39. 39.
    Cittadini A, Ishiguro Y, Stromer H, Spindler M, Moses AC, Clark R, Douglas PS, Ingwall JS, Morgan JP Insulin-like growth factor-1 but not growth hormone augments mammalian myocardial contractility by sensitizing the myofilament to Ca2+ through a wortmannin-sensitive pathway: studies in rat and ferret isolated muscles. Cire Res 1998; 83:50–59.CrossRefGoogle Scholar
  40. 40.
    Ren J, Sowers JR, Natavio M, Brown RA. Influence of age on inotropic response to insulin and insulin-like growth factor I in spontaneously hypertensive rats: role of nitric oxide. Proc Soc Exp Biol Med 1999; 221:46–52.PubMedCrossRefGoogle Scholar
  41. 41.
    Rodriguez-Tarduchy G, Collins MK, Garcia I, and Lopez-Rivas A. Insulin-like growth factor I inhibits apoptosis in IL-3-dependent hemopoietic cells. J Immunol 1992; 149:535–540.PubMedGoogle Scholar
  42. 42.
    Muta K, and Krantz SB. Apoptosis of human erythroid colony-forming cells is decreased by stem cell factor and insulin-like growth factor I as well as erythropoietin. J Cell Physiol 1993; 156:264–274.PubMedCrossRefGoogle Scholar
  43. 43.
    Muta K, Krantz SB, Bondurant MC, Wickrema A. Distinct roles of erythropoietin, insulin-like growth factor I, and stem cell factor in the development of erythroid progenitor cells. J Clin Invest 1994; 94:34–43.PubMedCrossRefGoogle Scholar
  44. 44.
    Gluckman BD, Guan J, Beilharz EJ, Klempt ND, Klempt M, Miller O, Sirimanne E, Dragunow M, Williams CE. The role of the insulin-like growth factor system in neuronal rescue. Ann NY Academy of Science 1993; 692:138:148.Google Scholar
  45. 45.
    Neff NT, Perevette D, Houenou LJ, Lewis ME, Glicksman MA, Yin QW, Oppenheim RW. Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival. J Neurobiol 1993; 24:1578–1588.PubMedCrossRefGoogle Scholar
  46. 46.
    Christofori G, Naik B, and Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 1994; 369:414–417.PubMedCrossRefGoogle Scholar
  47. 47.
    Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman HL, Kajstura J, Rubin R, Zoltick B, Baserga R. The insulin-like growth factor I receptor protects tumor cells from apoptosis in vivo. Cancer Res 1995; 55:2463–2469.PubMedGoogle Scholar
  48. 48.
    Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin. Invest 1995; 95:1897–1905.PubMedCrossRefGoogle Scholar
  49. 49.
    Bennett MR, Evan GI, Schwartz SM. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary arteriosclerotic plaques. J Clin Invest 1995; 95:2266–2274.PubMedCrossRefGoogle Scholar
  50. 50.
    Buerke M, Murohara T, Skurk C, Nuss C, Tomaselli K, Lefer AM. Cardioprotective effect of insulin-like growth factor I in myocardial ischemia followed by reperfusion. Proc Natl Acad Sci USA 1995; 92:8031–8035.PubMedCrossRefGoogle Scholar
  51. 51.
    L¨ª Q, Li B, Wang X, Leri A, Jana KP, Liu Y, Kajstura J, Baserga R, Anversa P. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest 1997; 100:1991–1999.CrossRefGoogle Scholar
  52. 52.
    Wang L, Ma W, Markovich R, Chen JW, Wang PH. Regulation of cardiomyocyte apoptotic signaling by insulin-like growth factor I. Circ Res 1998; 83:516–522.PubMedCrossRefGoogle Scholar
  53. 53.
    Leri A, Liu Y, Claudio PP, Kajstura J, Wang X, Wang S, Kang P, Malhotra A, Anversa P. Insulin-like growth factor-1 induces Mdm2 and down-regulates p53, attenuating the myocyte renin-angiotensin system and stretch-mediated apoptosis. Am J Pathol 1999; 154:567–580.PubMedCrossRefGoogle Scholar
  54. 54.
    Cittadini A, Stromer H, Katz SE, Clark R, Moses AC, Morgan JP, Douglas PS. Differential cardiac effects of growth hormone and insulin-like growth factor-1 in the rat. A combined in vivo and in vitro evaluation. Circulation. 1996; 93:800–809.PubMedCrossRefGoogle Scholar
  55. 55.
    Duerr RL, Huang S, Miraliakbar HR, Clark R, Chien KR, Ross J. Insulin-like Growth factor-1 enhances ventricular hypertrophy and function during the onset of experimental cardiac failure. J Clin Invest 1995; 95:619–627.PubMedCrossRefGoogle Scholar
  56. 56.
    Stromer H, Cittadini A, Douglas PS, Morgan JP. Exogenously administered growth hormone and insulin-like growth factor-I alter intracellular Ca2+ handling and enhance cardiac performance. In vitro evaluation in the isolated isovolumic buffer-perfused rat heart. Circ Res 1996; 79:227–236.PubMedCrossRefGoogle Scholar
  57. 57.
    Ross J Jr, Hongo M. The role of hypertrophy and growth factors in heart failure. J Card Fail 1996; 2:5121–5128.CrossRefGoogle Scholar
  58. 58.
    Ambler GR, Johnston BM, Maxwell L, Gavin JB, Gluckman PD. Improvement of doxorubicin induced cardiomyopathy in rats treated with insulin-like growth factor I. Cardiovasc Res 1993; 27:1368–1373.PubMedCrossRefGoogle Scholar
  59. 59.
    Copland AC, Nair KS. Recombinant human insulin-like growth factor I increases forearm blood flow. J Clin Endocrinol Metab 1994; 79:230–232.CrossRefGoogle Scholar
  60. 60.
    Fryburg DA. IGF I exerts GH and insulin-like actions on human muscle protein metabolism. Am J Physiol 1994; 267:E331–E336.PubMedGoogle Scholar
  61. 61.
    Kiowski W, Stoschitsky K, Kim JH, Hussain MA, Froesch ER. Insulin-like growth factor-I causes endothelium-dependent arterial vasodilatation. Circulation 1994; 90:I-242 (Abstr.).Google Scholar
  62. 62.
    Russell-Jones DL, Bates AT, Umpleby AM, Hennessy TR, Bowes SB, Hopkins KD, Jackson N, Kelly J, Shojaee-Moradie F, Jones RH, Sonksen PH. A comparison of the effects of IGF-I and insulin on glucose metabolism, fat metabolism and the cardiovascular system in normal human volunteers. Eur J Clin Invest 1995; 25:403–411.PubMedCrossRefGoogle Scholar
  63. 63.
    Donath MY, Jenni R, Brunner HP, Anrig M, Kohli S, Glatz Y, Froesch ER. Cardiovascular and metabolic effects of insulin-like growth factor I at rest and during exercise in humans J Clin Endocrinol Metab 1996; 81:4089–4094.PubMedCrossRefGoogle Scholar
  64. 64.
    Bisi G, Podio V, Valetto MR, Broglio F, Bertuccio G, DEl Rio G, Boghen MF, Berti F, Muller EE, Ghigo E. Radionuclide angiocardiographic evaluation of the cardiovascular effects of recombinant human IGF-I in normal adults. Eur J Endocrinol 1999; 140:322–327.PubMedCrossRefGoogle Scholar
  65. 65.
    Donath MY, Sutsch G, Yan XW, Piva B, Brunner HP, Glatz Y, Zapf J, Follath F, Froesch ER, Kiowski W. Acute cardiovascular effects of insulin-like growth factor I in patients with chronic heart failure. J Clin Endocrinol Metab 1998; 83:3177–3183.PubMedCrossRefGoogle Scholar
  66. 66.
    McGuffin Jr WL, Sherman BM, Roth J, Gorden P, Kahn CR, Roberts WC, Frommer PL. Acromegaly and cardiovascular disorders. A prospective study. Ann Intern Med 1974; 81:11–18.PubMedGoogle Scholar
  67. 67.
    Martins JB, Kerber RE, Sherman BM, Markus ML, Ehrhardt JC. Cardiac function in acromegaly. Circulation 1977; 56:863–869.PubMedCrossRefGoogle Scholar
  68. 68.
    Moller N, Schmitz O, Jorgensen JOL, Astrup J, Bak JF, Christensen SE, Alberti KG, Weeke J. Basal and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. J Clin Endocrinol Metab 1992; 74:1012–1019.PubMedCrossRefGoogle Scholar
  69. 69.
    Nikkila EA, Pelkonen R. Serum lipids in acromegaly. Metabolism 1975; 24:829–838.PubMedCrossRefGoogle Scholar
  70. 70.
    Guler H-P, Schmid C, Zapf J, Froesch ER. Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci USA 1989; 86:2868–2872.PubMedCrossRefGoogle Scholar
  71. 71.
    Zenobi PD, Graf S, Ursprung H, Froesch ER. Effects of insulin-like growth factor I on glucose tolerance, insulin levels and insulin secretion. J Clin Invest. 1992; 89:1908–1913.PubMedCrossRefGoogle Scholar
  72. 72.
    Froesch ER, Hussain MA. Recombinant human insulin-like growth factor-I: a therapeutic challenge for diabetes mellitus. Diabetologia 1994; 37:179–185.CrossRefGoogle Scholar
  73. 73.
    Zenobi PD, Holzmann P, Glatz Y, Riesen WE, Froesch ER. Improvement of lipid profile in type 2 (non-insulin-dependent) diabetes mellitus by insulin-like growth factor I. Diabetologia 1993; 36:465–469.PubMedCrossRefGoogle Scholar
  74. 74.
    Bianda T, Zapf J, Froesch ER, Schmid C. Insulin-like growth factor-I lowers fasting and postprandial triglyceride levels without affecting chylomicron clearance in healthy men. J Intern Med 1999; 245:455–462.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Marc Y Donath
    • 1
  • Juergen Zapf
    • 1
  1. 1.Division of Endocrinology and DiabetesDept of Medicine, University HospitalZurich

Personalised recommendations